Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Tirzepatide combined with L-carnitine pairs the dual GIP/GLP-1 receptor agonist with an essential cofactor for mitochondrial fat oxidation. This combination is designed to maximize fat metabolism and energy production during the aggressive weight loss tirzepatide produces.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tirzepatide activates both GIP and GLP-1 receptors, producing superior appetite suppression and metabolic improvement compared to single-receptor agonists. L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation, ensuring that fat mobilized during aggressive caloric restriction is efficiently converted to energy rather than recirculated.
No commercially available product combines tirzepatide with L-carnitine. Compounding allows prescribers to deliver both agents in a single injection, optimizing both appetite reduction and fat utilization. Injectable L-carnitine achieves therapeutic concentrations impossible with oral supplements.
Compounded tirzepatide with L-carnitine combines the most effective weight-loss injectable available with a critical cofactor for fat metabolism. Tirzepatide's dual GIP/GLP-1 mechanism produces weight loss of up to 22.5% of body weight — substantially more than any single-receptor GLP-1 agonist. With that level of fat mobilization, ensuring efficient mitochondrial fatty acid oxidation becomes clinically important.
L-carnitine is the rate-limiting transporter for long-chain fatty acid entry into mitochondria. During rapid weight loss, the body mobilizes large amounts of stored fat. Without adequate carnitine, this fat cannot be efficiently burned, potentially leading to fatigue and suboptimal body composition outcomes.
This combination is particularly prescribed by providers focused on body recomposition — maximizing fat loss while preserving lean muscle mass and maintaining energy levels throughout treatment.
Tirzepatide — Dual GIP/GLP-1 Receptor Activation
Tirzepatide activates both GIP receptors (enhancing insulin sensitivity in adipose tissue and promoting fat mobilization) and GLP-1 receptors (suppressing appetite, slowing gastric emptying, stimulating glucose-dependent insulin release). The dual mechanism produces greater metabolic effects than either pathway alone.
L-Carnitine — Mitochondrial Fatty Acid Transport
L-carnitine is required for the CPT (carnitine palmitoyltransferase) shuttle system that moves long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Injectable L-carnitine achieves plasma levels 10–20x higher than oral supplementation, making it clinically more effective for supporting fat oxidation during aggressive weight loss.
Prescribed for patients with a documented clinical need for compounded tirzepatide who also benefit from fat metabolism optimization:
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
Athletic performance support, carnitine deficiency, metabolic syndrome, statin-induced myopathy
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
Typical tirzepatide + L-carnitine dosing:
Weeks 1–4: Tirzepatide 2.5mg + L-carnitine 200mg weekly
Weeks 5–8: Tirzepatide 5mg + L-carnitine 200mg weekly
Weeks 9–12: Tirzepatide 7.5mg + L-carnitine 200–500mg weekly
Weeks 13–16: Tirzepatide 10mg + L-carnitine 200–500mg weekly
Weeks 17+: Tirzepatide 12.5–15mg + L-carnitine 200–500mg weekly
Dosing is individualized. L-carnitine dose may increase alongside tirzepatide to support higher rates of fat mobilization.
Follow standard tirzepatide titration (2.5mg start, increase every 4 weeks). L-carnitine does not require titration and does not contribute to GI side effects. Some prescribers increase L-carnitine at higher tirzepatide doses to match accelerated fat mobilization.
Subcutaneous Injection — The standard and most common form. Both agents are combined in a single vial for weekly injection.
From tirzepatide:
From L-carnitine:
GI side effects are primarily from tirzepatide and typically improve with continued use.
Compounded tirzepatide + L-carnitine is a 503A patient-specific preparation. Injectable L-carnitine (Carnitor) is FDA-approved for carnitine deficiency. The combination is not FDA-approved. The FDA resolved the tirzepatide shortage in late 2024; compounding remains legal for patients with documented clinical needs.
Different combinations address different clinical needs. B12 supports general nutrient repletion and nerve health. L-carnitine specifically enhances fat oxidation at the mitochondrial level. Prescribers choose based on whether the primary goal is nutrient support (B12) or fat metabolism optimization (L-carnitine). Some patients may benefit from all three agents.
Tirzepatide is the primary weight-loss agent. L-carnitine supports the body's ability to efficiently burn the fat that tirzepatide mobilizes. While individual studies support L-carnitine's role in fat oxidation during caloric restriction, large-scale combination trials are not yet published. The rationale is based on complementary mechanisms.
Typical pricing ranges from $229 to $529 per month depending on dose and pharmacy. Compounding Finder helps you compare options from multiple licensed pharmacies.
Yes. Compounded tirzepatide + L-carnitine requires a valid prescription from a licensed healthcare provider.
1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
2. Pooyandjoo M, et al. The Effect of (L-)Carnitine on Weight Loss in Adults: A Systematic Review and Meta-Analysis. Obes Rev. 2016;17(10):970-976.
3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
